Eli Lilly And Stock Beta
| LLY Stock | EUR 751.40 5.60 0.75% |
Eli Lilly and fundamentals help investors to digest information that contributes to Eli Lilly's financial success or failures. It also enables traders to predict the movement of Eli Stock. The fundamental analysis module provides a way to measure Eli Lilly's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eli Lilly stock.
Eli |
Eli Lilly and Company Beta Analysis
Eli Lilly's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Eli Lilly Beta | 0.35 |
Most of Eli Lilly's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eli Lilly and is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Eli Lilly and has a Beta of 0.3494. This is 59.37% lower than that of the sector and 70.14% lower than that of the Beta industry. The beta for all Germany stocks is notably lower than that of the firm.
Eli Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eli Lilly's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eli Lilly could also be used in its relative valuation, which is a method of valuing Eli Lilly by comparing valuation metrics of similar companies.Eli Lilly is currently under evaluation in beta category among its peers.
As returns on the market increase, Eli Lilly's returns are expected to increase less than the market. However, during the bear market, the loss of holding Eli Lilly is expected to be smaller as well.
Eli Fundamentals
| Return On Equity | 0.63 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 337.36 B | |||
| Shares Outstanding | 952.35 M | |||
| Shares Owned By Insiders | 0.10 % | |||
| Shares Owned By Institutions | 84.35 % | |||
| Price To Earning | 12.38 X | |||
| Price To Book | 34.47 X | |||
| Price To Sales | 11.21 X | |||
| Revenue | 28.54 B | |||
| Gross Profit | 21.91 B | |||
| EBITDA | 8.66 B | |||
| Net Income | 6.24 B | |||
| Cash And Equivalents | 2.2 B | |||
| Cash Per Share | 2.39 X | |||
| Total Debt | 14.74 B | |||
| Debt To Equity | 648.20 % | |||
| Current Ratio | 1.12 X | |||
| Book Value Per Share | 11.83 X | |||
| Cash Flow From Operations | 7.08 B | |||
| Earnings Per Share | 6.49 X | |||
| Price To Earnings To Growth | 2.21 X | |||
| Target Price | 407.12 | |||
| Number Of Employees | 39 K | |||
| Beta | 0.35 | |||
| Market Capitalization | 275.94 B | |||
| Total Asset | 49.49 B | |||
| Z Score | 10.8 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 2.42 % | |||
| Net Asset | 49.49 B | |||
| Last Dividend Paid | 3.92 |
About Eli Lilly Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eli Lilly and's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eli Lilly using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eli Lilly and based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Eli Stock
When determining whether Eli Lilly offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.